Press release

On 1 May 2025, Maurits Wolleswinkel will assume the role of CEO of NRG PALLAS, succeeding Peter Luijten, who has served as interim CEO since 1 November 2024.

Remco van Lunteren, Chairman of NRG PALLAS' Supervisory Board: "We are delighted to announce that Maurits Wolleswinkel will become CEO of NRG PALLAS from 1 May 2025. Maurits will lead the organisation into a new era as a state-owned company, building on our position as one of the world's largest producers of medical isotopes. His extensive experience in the international radiotherapy market will greatly benefit NRG PALLAS. With Maurits at the helm, our organisation can seize new opportunities in isotope development and strengthen our expertise in nuclear technology."

Maurits Wolleswinkel takes office at a key moment for NRG PALLAS. The European Commission's state aid procedure was successfully completed in 2024, and financing for the construction of the PALLAS-reactor has been secured. From 1 January 2025, NRG PALLAS will operate as one legal entity and will be converted into a state-owned company in 2025, with the Ministry of Health, Welfare and Sport as its shareholder. Preparations for the construction of the new PALLAS-reactor have started.

Incoming CEO Maurits Wolleswinkel: "It is a tremendous honour to lead the new company NRG PALLAS. Radiation and its unique applications are familiar to me, and I hope to leverage my international medical technology experience to advance NRG PALLAS. I am particularly excited to work in the Netherlands and collaborate with our international clients and partners, with almost 1,000 passionate colleagues, to shape the ‘Nuclear. For Life‘ ambitions together”.

The transition of responsibilities will occur on 1 May 2025. Until then, Maurits Wolleswinkel will focus on completing his duties as an Executive Committee member of the Swedish listed company Elekta. Peter Luijten will continue as interim CEO of NRG PALLAS until May 2025 and will remain for a few months thereafter to assist Maurits during his transition period.

About NRG PALLAS
NRG PALLAS is a global leader in nuclear solutions, specialising in the production of medical isotopes and the development of advanced nuclear technologies. Utilising the High Flux Reactor, NRG PALLAS produces medical isotopes for the diagnosis and therapeutic treatment of life-threatening diseases. Preparations are currently underway for the construction of the new PALLAS reactor, which will replace the HFR.